Addendum: Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition

Kemper M; Evers G; Schulze AB; Sperveslage J; Schülke C; Lenz G; Herold T; Hartmann W; Schildhaus HU; Bleckmann A

Research article (journal) | Peer reviewed

Details about the publication

Journal: Oncotarget

Volume: 13

Page range: 1216-1216

Status: Published

Release year: 2022 (02/11/2022)

Language in which the publication is written: English

Keywords: ALK; ALK inhibitors; KRAS; NSCLC; resistance mutations.

Bleckmann, Annalen	Westdeutsches Tumorzentrum (WTZ) Netzwerkpartner Münster
Evers, Georg	Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A)
Hartmann, Wolfgang	Gerhard Domagk Institute of Pathology
Kemper, Marcel	Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A)
Lenz, Georg	Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A)
Schülke, Christoph	Clinic of Radiology
Schulze, Arik Bernard	Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A)
Sperveslage, Jan	Gerhard Domagk Institute of Pathology